| 15.87 0.74 (4.89%) | 10-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 18.83 | 1-year : | 19.6 |
| Resists | First : | 16.12 | Second : | 16.78 |
| Pivot price | 15.92  |
|||
| Supports | First : | 15.06 | Second : | 12.52 |
| MAs | MA(5) : | 15.64 |
MA(20) : | 15.95 |
| MA(100) : | 13.8 |
MA(250) : | 11.48 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 22 |
D(3) : | 25.2 |
| RSI | RSI(14): 50.1 |
|||
| 52-week | High : | 17.42 | Low : | 8.11 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ DCTH ] has closed above bottom band by 45.5%. Bollinger Bands are 42.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 15.96 - 16.04 | 16.04 - 16.12 |
| Low: | 14.98 - 15.06 | 15.06 - 15.14 |
| Close: | 15.74 - 15.87 | 15.87 - 16 |
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.
Sun, 04 Oct 2026
Delcath Systems Inc. Research & Ratings | DCTH - Barron's
Fri, 02 Oct 2026
Delcath Systems Stock Price Forecast. Should You Buy DCTH? - StockInvest.us
Tue, 15 Sep 2026
Are Medical Stocks Lagging Delcath Systems (DCTH) This Year? - Yahoo Finance
Mon, 31 Aug 2026
Delcath Systems will attend two investor conferences in September - Stock Titan
Sat, 29 Aug 2026
Delcath Systems (DCTH) Holds Near $16.34 as Traders Eye Support and Resistance Zones - Sentiment Extreme - careplusvn.com
Tue, 11 Aug 2026
Here's Why Delcath Systems, Inc. (DCTH) is a Great Momentum Stock to Buy - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 35 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 8 (%) |
| Held by Institutions | 51.7 (%) |
| Shares Short | 2,360 (K) |
| Shares Short P.Month | 2,690 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.5 |
| Profit Margin | 0.5 % |
| Operating Margin | 8.2 % |
| Return on Assets (ttm) | -0.9 % |
| Return on Equity (ttm) | 0.4 % |
| Qtrly Rev. Growth | 20.6 % |
| Gross Profit (p.s.) | 2.39 |
| Sales Per Share | 2.74 |
| EBITDA (p.s.) | -0.05 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 20 (M) |
| Levered Free Cash Flow | 18 (M) |
| PE Ratio | 1587 |
| PEG Ratio | 1.6 |
| Price to Book value | 4.53 |
| Price to Sales | 5.77 |
| Price to Cash Flow | 28.11 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|